Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery
- PMID: 39365699
- DOI: 10.1016/j.celrep.2024.114784
Proteome-wide CETSA reveals diverse apoptosis-inducing mechanisms converging on an initial apoptosis effector stage at the nuclear periphery
Abstract
Cellular phenotypes of apoptosis, as well as the activation of apoptosis caspase cascades, are well described. However, sequences and locations of early biochemical effector events after apoptosis initiation are still only partly understood. Here, we use integrated modulation of protein interaction states-cellular thermal shift assay (IMPRINTS-CETSA) to dissect the cellular biochemistry of early stages of apoptosis at the systems level. Using 5 families of cancer drugs and a new CETSA-based method to monitor the cleavage of caspase targets, we discover the initial biochemistry of the effector stage of apoptosis for all the studied drugs being focused on the peripheral nuclear region rather than the cytosol. Despite very different candidate apoptosis-inducing mechanisms of the drug families, as revealed by the CETSA data, they converge into related biochemical modulations in the peripheral nuclear region. This implies a higher control of the localization of the caspase cascades than previously anticipated and highlights the nuclear periphery as a critical vulnerability for cancer therapies.
Keywords: CETSA; CP: Cancer; CP: Cell biology; IAP inhibitors; PI3K inhibitors; apoptosis; cancer drugs; caspase cleavage; glutathione metabolism; mass spectrometry; proteomics; taxanes.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests P.N. is the inventor of patents related to the CETSA method and is a cofounder and board member of Pelago Biosciences AB. P.N., A.D.R., S. Lööf, S.B., and M.-A.G. are inventors on patent applications related to CETSA-based biomarkers. K.G.W. is a cofounder and shareholder of Aprea Therapeutics, a company that develops p53-targeted cancer therapy, including APR-246. K.G.W. has previously received financial support and a salary from Aprea Therapeutics. G.A.W. is a full-time employee of Astex Pharmaceuticals.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous